Gland Pharma and Neuland Laboratories have launched a CDMO partnership to manufacture sterile active pharmaceutical ingredients. Neuland has provided a ₹40 crore corporate guarantee for the project, which will add 1,400 kg of annual capacity at Gland’s Visakhapatnam facility to meet demand for complex drugs.
Hyderabad-based pharmaceutical companies Gland Pharma and Neuland Laboratories have entered into a long-term contract development and manufacturing organization (CDMO) partnership. The collaboration focuses on the production of sterile active pharmaceutical ingredients (APIs), specifically targeting the growing market for microparticle depot products and other complex sterile formulations.
As part of the agreement, Gland Pharma will establish a dedicated sterile manufacturing suite at its existing facility in JNPC, Visakhapatnam. This new infrastructure is expected to add approximately 1,400 kilograms of annual production capacity. The facility is being designed to meet global quality standards, including compliance with current Good Manufacturing Practices (cGMP), the US Food and Drug Administration (USFDA), and European Union regulations.
To support the project, the board of Neuland Laboratories has approved a ₹40 crore corporate guarantee in favor of Gland Pharma. This financial commitment supports a planned loan license agreement, ensuring the project moves forward with defined backing. The partnership announcement comes on the same day Neuland Laboratories reported its Q1 FY27 financial results, which showed a strong net profit of ₹147.4 crore and EBITDA margins of 35.5%, indicating a solid financial base to support such expansion efforts.
This strategic alliance leverages the complementary strengths of both firms. Neuland Laboratories brings its expertise in complex API development and intricate chemistry, while Gland Pharma contributes its established history in sterile manufacturing and aseptic processing. By combining these capabilities, the companies aim to offer a complete solution that covers development, scale-up, and commercial production of high-value sterile products.
While the partnership aims to capture demand for advanced drug products, investors may consider the risks inherent in large-scale pharmaceutical projects. These include potential execution delays during the construction and commissioning of the new manufacturing suite. Additionally, the project is subject to regulatory approvals from authorities like the USFDA. Any delay in securing these clearances could impact the timeline for commercial production. Furthermore, the ₹40 crore corporate guarantee represents a contingent liability for Neuland Laboratories, and the capital-intensive nature of such expansions can exert pressure on cash flows if not managed efficiently.
The next steps for investors to track include the progress of construction at the Visakhapatnam site, the timeline for regulatory audits, and updates on the eventual commercialization of the sterile APIs produced at the new suite. Management commentary regarding the ramp-up of this capacity and its contribution to future revenue will also be an important monitorable.